Astellas Pharma has acquired Xyphos Biosciences for up to $665 million, in a deal intended to bolster the buyer’s cancer immunotherapy pipeline with Xyphos’ Advanced Cellular Control through Engineered Ligands (ACCEL) technology platform.
Symbiotic Capital launches with $600 million-plus in capital, about half of which has been lent to advanced-stage life sciences companies.
Lentiviral vectors (LVVs) are becoming increasingly prominent in the advanced therapy space, according to Rentschler Biopharma.
The scientist will focus on brain repair as a model system, with the ultimate goal of harnessing microglial states.
Radiopharmaceuticals work like radiotherapy but provide localized—rather than external—delivery of a radioisotope.
A team of researchers concluded that multivariate data analysis can be applied to large data sets to enable deep learning.
Controlling a biopharmaceutical continuous process is a conceptual shift for an industry built on batch-mode manufacturing.
Recent growth in the heterogeneity of the biotech pipeline has increased demand for microbial manufacturing capacity.
KromaTiD reports that the dGH platform, a cytogenomics-based technology, can detect gene editing–associated structural variants at high resolution on a cell-by- cell basis.
The researchers’ ambition was to create a nimble, versatile ChatGPT-like AI platform that can perform a broad range of cancer evaluation tasks.
Scientists also found non-tumor cells that are neuron-glia hybrids, suggesting that this cell population may contribute to healthy brain function.
